All News

TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

d Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

d MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
uric%20acid.crystals.gout_.JPG

No Benefit to More Intensive Urate Lowering in Gout

d Jack Cush, MD

While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.

Read Article
virtual online learning home office zoom

Consensus Best Practices for Virtual Care in Rheumatology

d Jack Cush, MD

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

Read Article
Young,doctor,mask

ACR Fellow Training Subcommittee Report on Pandemic Experiences

d Jack Cush, MD

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

Read Article
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTX https://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK

Links:

Dr. John Cush RheumNow ( View Tweet)
Downward Effects! Real world data from 22,934 UK #RA pts starting 1st b/tsDMARD shows DAS remission/LDA achieved in 17% following 1st line, 13% 2nd, & 8-13% with 3rd thru 6th DMARD. (LDA in 29% 1st line, 23% 2nd, 17–22% 3rd thru 6th) https://t.co/cZt0BvhK6I https://t.co/blemgbDoN8

Links:

Dr. John Cush RheumNow ( View Tweet)
Despite COVID, revenues for half of top 20 pharma companies grew 10-40% in 2021 Revenues (billions) 1 J&J $97 2 Pfizer $81 3 Roche $62 4 Abbvie $56 5 Novartis $51 6 Merck $48 7 BMS $46 8 GSK $46 9 Sanofi $44 10 AZ $37 https://t.co/rSovxIXOId https://t.co/GuKIBYoML6

Links:

Dr. John Cush RheumNow ( View Tweet)
Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/Om8CwbmlgN https://t.co/872E7HGOp2

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Laura Coates discusses Precision Medicine in PsA. https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH

Links:

Dr. John Cush RheumNow ( View Tweet)
The value of COVID Vaccine after COVID infection - Vax Effx after COVID=445% after 2 doses & 58% after booster during Delta COVID. During Omicron, 35% effect after 2 doses and 68% after a booster dose - best protection conferred by booster https://t.co/VXi70r2nS3 https://t.co/Oeuet3pudD

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic Reasons why PsA patient can lose biologic efficacy and what to do about it QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Combined Clinics for PsA Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week. https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH

Links:

Dr. John Cush RheumNow ( View Tweet)
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF

Links:

Dr. John Cush RheumNow ( View Tweet)
How long does a good response last to a biologic? How and When to distinguish between flares and intercurrent illness. QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/ZIWQysY5dd https://t.co/RZrS6FfUTV

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367

Links:

Dr. John Cush RheumNow ( View Tweet)
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×